Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business

businesswire.com
ATR The article announces a leadership change in Aptar's Pharma business with the appointment of Virginie Maes. While the appointment is presented positively, highlighting her experience and confidence in her leadership, the core business and its future performance are discussed with forward-looking statements and risk factors, preventing a strongly bullish or bearish sentiment.

Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business CRYSTAL LAKE, Ill.--( BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027.

"Virginie brings significant global experience, a strong customer focus and a proven ability to lead and grow complex businesses. I am confident she is the right leader to take our Pharma business forward."

Maes joins Aptar from Amcor, where she currently leads its global Flexibles Pharma and Medical packaging business, spanning North America, Latin America, EMEA and Asia. During her career at Amcor, she has held senior leadership roles across pharma, medical, strategy and business development. She brings extensive experience in global customer relationships, growth and transformation, operational performance and building highly engaged teams. Earlier in her career, Maes worked at McKinsey & Company, Terra Firma Capital Partners and Morgan Stanley. She holds an MBA from Harvard Business School, a Master’s in Financial Management from Vlerick Business School and a Master’s in Applied Economics from Ghent University.

“Virginie brings significant global experience, a strong customer focus and a proven ability to lead and grow complex businesses. I am confident she is the right leader to take our Pharma business forward,” said Gael Touya, President and Chief Executive Officer of Aptar. “She will lead a business with strong market positions, deep scientific and technical expertise and significant bench strength. Our focus is on continuing to become the partner of choice for our customers, solving their most complex challenges and creating value beyond the product.”

“I am excited to join Aptar and a Pharma business with strong leadership positions, deep expertise and a clear commitment to its customers,” said Virginie Maes. “The opportunity to work alongside our teams and customers to help them succeed, bringing together our technologies, services and expertise across the value chain from formulation through commercialization is what I’m most enthusiastic about. Ultimately, everything we do should be focused on helping our customers deliver solutions that support patients and improve their lives.”

About Aptar

Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.

This press release contains forward-looking statements, including statements regarding Ms. Maes’s appointment and its anticipated effective date, the future leadership, strategy and performance of the Company’s Pharma business, and the Company’s customer and growth initiatives. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues,” “working,” “support,” “advance” and other similar expressions, or future or conditional verbs such as “will,” “should,” “would” and “could,” which are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the timing of Ms. Maes’s commencement of employment; the successful transition of leadership of our Pharma business; our ability to attract and retain key personnel; our ability to execute our Pharma growth strategy and maintain customer relationships and market positions; changes in customer demand and the development, regulatory approval and commercialization of our customers’ products; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.